Earnings call transcript: Neogen beats Q1 2026 forecasts, shares swing higher

Neogen reported fiscal Q1 2027 adjusted EPS of $0.08 versus $0.05 expected and revenue of $222.8 million versus $204.7 million expected; core revenue grew 8.1% year over year for a fifth consecutive quarter. Adjusted EBITDA margin expanded 170 basis points to 18.7%, and the company raised fiscal 2027 revenue guidance to $885 million–$890 million and adjusted EBITDA guidance to $181 million–$183 million. Shares fell 8.07% in regular trading to $11.96, then rose 9.7% from the close to $13.12 after hours; management said fiscal Q2 is expected to be the weakest quarter for core growth, while the Petrifilm transfer remains on track.

Analysis

NEOG: improving execution, but the quarter overstates the near-term run rate. The key underwriting question is whether commercial gains persist after timing benefits unwind—not whether management can print another headline beat. The roughly 300bp lift from pulled-forward orders and distributor comparisons implies a meaningfully lower underlying Q1 pace; management’s ~3.5% first-half growth outlook makes Q2 the immediate test. A weak Q2 would challenge the new sales-model narrative even if full-year guidance remains intact.

Margin quality is also less straightforward than the 170bp year-over-year EBITDA expansion suggests: first-half margins are expected around Q1 levels, full-year margins remain roughly flat versus FY26, and the 200–300bp Petrifilm-related opportunity is not expected until FY29. The transition is therefore a multi-quarter supply and execution risk before it becomes a structural margin catalyst. One SKU validation reduces technical uncertainty, not the risk of disruption across the remaining SKUs.

Over 1–3 months, watch Q2 organic growth, duplicate manufacturing costs, customer continuity/inventory, and regulatory clearance of the genomics sale. The expected proceeds would support deleveraging, but are neither closed nor included as a completed balance-sheet improvement. Over 6–18 months, sustained share gains and working-capital discipline matter more than innovation-partnership claims until they translate into commercial revenue.

The after-hours reversal may price in a durable inflection prematurely: the stock already carries substantial momentum, while reported cash generation and leverage leave less room for execution slippage. No clear read-through to 3M’s consolidated earnings is established by the transition disclosure.

Key Decisions for Investors

• Do not chase the after-hours gap. Keep NEOG on a watchlist; consider a staged long only after Q2 confirms growth beyond timing effects and Petrifilm supply remains uninterrupted. Reassess if core growth falls below management’s first-half trajectory or transition costs materially pressure margins.
• Treat the genomics divestiture as a catalyst, not a base-case balance-sheet fact. Verify regulatory approval and closing; delay or a lower-than-expected net proceeds figure would weaken the deleveraging case.
• Track Petrifilm SKU-by-SKU validation, customer service levels, inventory/write-offs, and duplicate costs over coming quarters. Any supply interruption or rising transition costs would falsify the de-risking thesis; the FY29 margin target is too distant to underwrite as a near-term catalyst.
• No MMM trade on this disclosure alone: verify whether 3M retains material ongoing supply, licensing, or transition economics before assigning a financial read-through.